Evaluation of Folate-targeted ChemoRad Nanoparticle as Intraperitoneal Chemoradiotherapy for Ovarian Cancer

Abstract

Ovarian peritoneal metastasis is the leading cause of morbidity and mortality in ovarian cancer patients. While intraperitoneal (IP) chemotherapy and IP radioisotope therapy have shown favorable clinical results, both lead to significant toxicities. Chemoradiotherapy has been shown to be superior to either therapy alone in many cancers, but has not yet been evaluated in ovarian cancer due to concerns of toxicity. Advances in nanotechnology have enabled the development of biologically targeted nanoparticle (NP) therapeutic carriers.